CAPHRA calls for regulated access to e-cigarettes in Australia

Dec.16.2022
CAPHRA calls for regulated access to e-cigarettes in Australia
CAPHRA submits consultation document to TGA for access to legal electronic cigarettes and nicotine in Australia.

According to a submission by the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), just over 1% of people capable of writing nicotine scripts actually do so. Less than one-third of authorized prescribers are publicly available for adult smokers seeking to switch to nicotine e-cigarettes due to Australia's failed medicalized model.


CAPHRA has submitted a consultation paper to the Therapeutic Goods Administration (TGA) in Australia, discussing various options for legally obtaining electronic cigarettes and nicotine.


Australia remains the only Western democracy that requires a prescription for nicotine electronic cigarettes. The public consultation period regarding the proposed reform on the regulation of nicotine e-cigarette products in Australia began on November 30th and ended on January 16th, 2023.


Over the past decade, smoking rates in Australia have remained stable, particularly among vulnerable and disadvantaged communities. Nancy Loucas, the executive coordinator of CAPHRA, stated that "electronic cigarettes are one of the most effective methods for smokers worldwide to quit smoking, and access to them at retail outlets should have been restricted long ago.


CAPHRA stated that several countries, including the European Union, the United Kingdom, New Zealand, and Canada, are currently utilizing electronic cigarettes and reduced harm products to influence the rapid decline in smoking prevalence in these countries.


Ms. Lucas stated that the most deadly product to the public, combustible tobacco, is still readily available at any ordinary retailer, which is a mockery of public health.


Australia needs to determine whether their nicotine policy decisions are based on science, evidence, and facts to promote and maintain the health of their population, or if they choose money over health regarding tobacco consumption taxes and other possible funding they may receive due to their severe policy, which has proven to be a failure, according to CAPHRA.


Australian politicians and officials may not like to hear it, but if they want to see success, they need only cross the Tasman Sea. New Zealand has adopted an active harm reduction approach towards tobacco, and in the past decade, with the implementation of the Smokefree 2025 goal, their overall smoking rate has halved. Now they aim to achieve a regular smoking rate of only 5% or less. "Ms Loucas said.


Similarly, CAPHRA wrote that if youth access is truly a concern for Australian policymakers, the only solution is proper regulation and imposing strict fines and license revocations for non-compliant retailers. New Zealand's 2020 e-cigarette legislation and subsequent regulations achieved this.


According to Ms. Loucas, New Zealand has an effective consumer framework. In fact, in the past year alone, over 150,000 New Zealanders have switched from deadly combustible products to safer nicotine alternatives.


The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) believes that a regulated consumer market will enable Australia to have necessary control over the quality and quantity of products sold by community retailers. It also allows for products to be restricted to adults only – similar to alcohol and combustible cigarettes.


The report points out that there is currently a prevalence of unregulated black market products in Australia, with no regulatory control over their content or access for individuals under the age of 18.


We, on behalf of our nine member organizations, have submitted a letter of objection to the consultation document advocating for the 'gateway theory.' Despite the document's claim of evidence that electronic cigarettes lead to youth smoking, the gateway theory has been both confirmed and questioned by numerous international research institutions. Ms. Loucas stated that electronic cigarettes are an exit from smoking, not an entrance.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20